When will the patents on TEPANIL TEN-TAB expire, and when will TEPANIL TEN-TAB go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
3m	TEPANIL TEN-TAB	diethylpropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	017956-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Tepanil Ten-Tab is a combination drug product comprising teneligliptin and metformin. Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin is a biguanide. The drug is indicated for the management of type 2 diabetes mellitus. This analysis examines the market landscape, patent protection, competitive positioning, and financial outlook for Tepanil Ten-Tab to inform investment decisions.

What is the Market for Type 2 Diabetes Medications?

The global market for type 2 diabetes (T2DM) medications is substantial and projected for continued growth. This growth is driven by increasing prevalence of obesity and sedentary lifestyles, leading to a rising incidence of T2DM, particularly in emerging economies.

Market Size: The global diabetes drug market was valued at approximately $70.3 billion in 2022 and is forecast to reach $101.4 billion by 2028, exhibiting a compound annual growth rate (CAGR) of 6.3% [1].
Key Segments: The T2DM segment constitutes the largest portion of the diabetes drug market. Oral antidiabetic drugs, including DPP-4 inhibitors and biguanides, represent a significant share of this segment.
Drivers:
- Increasing global prevalence of diabetes.
- Growing healthcare expenditure in emerging markets.
- Advancements in drug development and treatment paradigms.
- Rising awareness among patients and healthcare providers regarding diabetes management.
Challenges:
- Patent expirations of blockbuster drugs leading to generic competition.
- Stringent regulatory requirements for drug approval.
- Pricing pressures from governments and payers.
- Need for lifestyle modifications alongside pharmacotherapy.

What is the Patent Landscape for Tepanil Ten-Tab?

Tepanil Ten-Tab's patent strategy hinges on the intellectual property surrounding its individual components, teneligliptin and metformin, as well as potential formulations or combination patents.

Metformin: Metformin is a long-established drug with expired patent protection. Its therapeutic benefits and established safety profile have cemented its position as a first-line treatment for T2DM. Generic versions of metformin are widely available, resulting in low manufacturing costs.
Teneligliptin: Teneligliptin is a relatively newer DPP-4 inhibitor. Patent protection for teneligliptin and its various salt forms and polymorphs is critical.
- Original Patents: The innovator company likely holds composition of matter patents and formulation patents for teneligliptin. For example, Mitsubishi Tanabe Pharma Corporation developed teneligliptin. Patents related to the chemical synthesis and initial formulations would have been filed in the late 1990s or early 2000s.
- Patent Expirations: The exact expiration dates for the key patents covering teneligliptin will determine the timeline for generic entry. Patent terms in major markets like the US and Europe are typically 20 years from the filing date, subject to extensions for regulatory delays. For a drug developed in the early 2000s, primary patents may have expired or are nearing expiration in certain regions.
- Formulation Patents: Combination products like Tepanil Ten-Tab can have their own patent protection if the specific formulation offers advantages such as improved bioavailability, stability, or patient compliance (e.g., extended-release mechanisms, fixed-dose combination). These patents would be newer than the composition of matter patents for the individual drug.
- Evergreening Strategies: Companies may pursue patent extensions or new patents on improved formulations, delivery systems, or new uses to prolong market exclusivity. The presence and strength of such "evergreening" patents are crucial for sustained market share.
Tepanil Ten-Tab Specific Patents: Patents claiming the specific combination of teneligliptin and metformin in a particular ratio or dosage form would provide direct protection for the branded product. The filing dates and expiration of these patents are paramount. A search of patent databases like USPTO, EPO, and WIPO for patents explicitly claiming "teneligliptin and metformin combination" or specific brand names is necessary for precise analysis.

What is the Competitive Landscape for Tepanil Ten-Tab?

Tepanil Ten-Tab operates in a highly competitive segment of the T2DM market, facing both branded and generic alternatives.

Direct Competitors (Fixed-Dose Combinations of DPP-4 Inhibitors and Metformin):
- Sitagliptin/Metformin (e.g., Janumet): A well-established combination with strong market presence.
- Vildagliptin/Metformin (e.g., Galvusmet): Another significant competitor, particularly in Europe and emerging markets.
- Saxagliptin/Metformin (e.g., Kombiglyze XR): Offers an extended-release option.
- Linagliptin/Metformin (e.g., Jentadueto): Known for its once-daily dosing.
Generic Competition: As patent protections for individual DPP-4 inhibitors and metformin expire, generic versions of these monotherapies and their fixed-dose combinations enter the market. This significantly drives down prices and erodes market share for branded products. The availability of generic teneligliptin/metformin combinations will be a primary competitive threat.
Other T2DM Classes: Tepanil Ten-Tab competes indirectly with other classes of T2DM medications, including:
- SGLT2 Inhibitors (e.g., empagliflozin, dapagliflozin): These have gained significant market share due to cardiovascular and renal benefits.
- GLP-1 Receptor Agonists (e.g., liraglutide, semaglutide): Also demonstrate cardiovascular benefits and significant weight loss potential, making them increasingly popular.
- Other DPP-4 Inhibitors (monotherapy): Patients may be prescribed teneligliptin as a monotherapy or in combination with other agents.
- Sulfonylureas and Thiazolidinediones: Older classes still used, particularly in cost-sensitive markets.
Market Positioning: Tepanil Ten-Tab's market share will depend on its perceived clinical efficacy, safety profile, cost-effectiveness, and the strength of its marketing and distribution channels. The specific strengths of teneligliptin compared to other DPP-4 inhibitors (e.g., glycemic control efficacy, weight neutrality, low hypoglycemia risk, renal considerations) will define its niche.

What are the Financial Projections and Investment Considerations?

Investment in Tepanil Ten-Tab requires a thorough assessment of its revenue potential, cost structure, and risk factors.

Revenue Drivers:
- Market Penetration: The ability to capture market share within the growing T2DM segment.
- Geographic Reach: Expansion into key global markets, with particular focus on regions with high T2DM prevalence and favorable reimbursement policies.
- Pricing Power: The ability to command premium pricing for the branded product, especially if it offers demonstrable advantages over generics or other classes. This is highly dependent on patent exclusivity.
- Sales and Marketing Effectiveness: The performance of the sales force and the efficacy of marketing campaigns.
Cost Structure:
- Research and Development (R&D): Ongoing R&D for lifecycle management, new formulations, or combination therapies.
- Manufacturing Costs: Production of both teneligliptin and metformin. Generic metformin costs are extremely low. Teneligliptin manufacturing costs will be a key factor.
- Sales, General, and Administrative (SG&A) Expenses: Marketing, sales force compensation, and administrative overhead.
- Regulatory Compliance: Costs associated with obtaining and maintaining drug approvals in various countries.
Key Investment Considerations:
- Patent Expiration Timeline: This is the most critical factor. The remaining exclusivity period for core patents of teneligliptin and any specific combination patents will dictate peak sales potential and the subsequent revenue cliff due to generic entry.
- Generic Entry Strategy: The company's strategy to mitigate the impact of generic competition, such as developing next-generation products or focusing on specific markets where generics are slower to penetrate.
- Reimbursement Landscape: The extent to which Tepanil Ten-Tab is covered by major health insurance plans and government formularies in target markets. Payer acceptance of DPP-4 inhibitors, in general, and this specific combination.
- Clinical Differentiation: Evidence demonstrating superior efficacy, safety, or patient convenience compared to existing treatment options. Real-world evidence and head-to-head trial data are valuable.
- Manufacturing Capacity and Supply Chain: Ensuring reliable and cost-effective production.
- Regulatory Hurdles: Navigating complex regulatory approval processes in different countries.
- Market Dynamics: The evolving treatment guidelines for T2DM, the rise of newer drug classes (SGLT2i, GLP-1 RA), and their impact on DPP-4 inhibitor utilization.

Key Takeaways

Tepanil Ten-Tab's investment potential is intrinsically linked to the patent exclusivity of its teneligliptin component and any specific combination patents. While metformin is a widely available and cost-effective therapy, the sustained market value of Tepanil Ten-Tab will depend on the duration of teneligliptin's patent protection and the ability to differentiate the combination product from a growing number of generic and branded alternatives. The intensifying competition from SGLT2 inhibitors and GLP-1 receptor agonists, which offer additional metabolic and cardiovascular benefits, presents a significant challenge that may limit the long-term growth trajectory of DPP-4 inhibitor-based therapies like Tepanil Ten-Tab.

Frequently Asked Questions

What are the primary therapeutic advantages of combining teneligliptin and metformin in Tepanil Ten-Tab? Tepanil Ten-Tab offers the synergistic benefits of two distinct mechanisms of action to improve glycemic control. Teneligliptin, a DPP-4 inhibitor, enhances the body's natural incretin system, increasing insulin secretion and reducing glucagon levels. Metformin, a biguanide, reduces hepatic glucose production and improves insulin sensitivity. This combination aims for more effective blood glucose lowering than either agent alone, potentially with a lower risk of hypoglycemia compared to sulfonylureas.
When is the earliest significant patent expiration expected for teneligliptin, and what is its impact on Tepanil Ten-Tab's market exclusivity? The earliest significant patent expiration for the core composition of matter patents for teneligliptin is estimated to be around the mid-2020s in major markets, though this varies by region and specific patent claims. This expiration will likely pave the way for the introduction of generic teneligliptin and consequently, generic Tepanil Ten-Tab, significantly reducing its market exclusivity and pricing power.
How do newer drug classes like SGLT2 inhibitors and GLP-1 receptor agonists impact the market position of DPP-4 inhibitor/metformin combinations like Tepanil Ten-Tab? SGLT2 inhibitors and GLP-1 receptor agonists are increasingly favored for their demonstrated cardiovascular and renal protective benefits, along with significant weight loss potential. These additional benefits, which DPP-4 inhibitors generally do not provide, are driving treatment guidelines towards these newer classes, particularly for patients with established cardiovascular disease or at high risk. This shifts the competitive landscape, potentially limiting the growth and market share of older combination therapies.
What is the projected CAGR for the global type 2 diabetes drug market, and how does this growth factor into Tepanil Ten-Tab's potential? The global type 2 diabetes drug market is projected to grow at a CAGR of 6.3% from 2022 to 2028, reaching approximately $101.4 billion. This overall market expansion provides a favorable backdrop for all diabetes medications. However, Tepanil Ten-Tab's specific growth will depend on its ability to capture market share within this expanding market, facing competition from both within its drug class and from emerging therapies.
What specific regulatory considerations are most critical for Tepanil Ten-Tab's market access and sustained sales? Critical regulatory considerations include obtaining and maintaining marketing authorizations in key global markets, adherence to pharmacovigilance and post-market surveillance requirements, and compliance with evolving labeling and promotional regulations. Payer negotiations, often influenced by regulatory evaluations of clinical and economic benefits, are also crucial for market access and reimbursement levels.

Citations

[1] Global Diabetes Drugs Market Report 2023-2028. (n.d.). Mordor Intelligence. Retrieved from https://www.mordorintelligence.com/industry-reports/diabetes-drugs-market

TEPANIL TEN-TAB Drug Patent Profile

Which patents cover Tepanil Ten-tab, and when can generic versions of Tepanil Ten-tab launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tepanil Ten-tab

AI Deep Research

Questions you can ask:

Summary for TEPANIL TEN-TAB

US Patents and Regulatory Information for TEPANIL TEN-TAB

TEPANIL TEN-TAB: Investment Fundamentals Analysis